{"id":"teneligliptin-canagliflozin","safety":{"commonSideEffects":[{"rate":"null","effect":"Nasopharyngitis"},{"rate":"null","effect":"Hypoglycemia"},{"rate":"null","effect":"Ketoacidosis"},{"rate":"null","effect":"Urosepsis"},{"rate":"null","effect":"Urinary Tract Infection"}]},"_chembl":{"chemblId":"CHEMBL4594217","moleculeType":"Small molecule","molecularWeight":"462.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Teneligliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones. This leads to increased insulin release and decreased glucagon levels in the circulation in a glucose-dependent manner. Canagliflozin, on the other hand, works by inhibiting the reabsorption of glucose in the kidneys, thereby increasing glucose excretion in the urine and lowering blood glucose levels.","oneSentence":"Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:03.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT02220907","phase":"PHASE3","title":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":153},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":"Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tenelia","MP-513","Canaglu","TA-7284"],"phase":"phase_3","status":"active","brandName":"Teneligliptin/Canagliflozin","genericName":"Teneligliptin/Canagliflozin","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Used for Type 2 diabetes mellitus, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}